Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 25 August 2000:
Vol. 289. no. 5483, pp. 1266 - 1267
DOI: 10.1126/science.289.5483.1266
Prev | Table of Contents | Next

News of the Week

BIOETHICS:
Financial Conflicts Get More Scrutiny in Clinical Trials

Bruce Agnew

At a national conference on clinical research last week, the incoming head of the federal government's new Office for Human Research Protections, Greg Koski, surprised his audience by suggesting that some conflicts should be avoided. His support for the idea that scientists should have no financial ties to companies whose products they are testing hints at an upcoming shift in government rules that govern the relationship between scientists and the pharmaceutical industry. But most of the discussion at the conference revolved around questions of how to "manage" conflicts rather than do away with them.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Medical Innovation and Institutional Interdependence: Rethinking University-Industry Connections.
A. C. Gelijns and S. O. Thier (2002)
JAMA 287, 72-77
   Abstract »    Full Text »    PDF »
Conflict-of-Interest Policies for Investigators in Clinical Trials.
B. Lo, L. E. Wolf, and A. Berkeley (2000)
N. Engl. J. Med. 343, 1616-1620
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)